Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

• ClinicalTrials.gov Identifier: NCT02646748
• Recruitment Status: Active, not recruiting
• First Posted: January 6, 2016
• Last Update Posted: December 4, 2020
• Sponsor: Incyte Corporation
• Information provided by (Responsible Party): Incyte Corporation

Tracking Information

• First Submitted Date: January 4, 2016
• First Posted Date: January 6, 2016
• Last Update Posted Date: December 4, 2020
• Actual Study Start Date: January 25, 2016
• Actual Primary Completion Date: November 7, 2019 (Final data collection date for primary outcome measure)
• Current Primary Outcome Measures (submitted: December 19, 2019): Part 1: Evaluation of safety and tolerability as measured by the frequency, duration, and severity of adverse events [ Time Frame: Duration of study treatment and up to 120 days after the last dose of study drug ]
• Original Primary Outcome Measures (submitted: January 4, 2016): Evaluation of safety and tolerability as measured by the frequency, duration, and severity of adverse events [ Time Frame: Duration of study treatment and up to 120 days after the last dose of study drug ]

Current Secondary Outcome Measures (submitted: December 19, 2019)

• Part 1 and 2: Objective Response Rate (ORR) as determined by radiographic disease assessments per immune-related Response Evaluation Criteria In Solid Tumors (irRECIST) v1.1 criteria [ Time Frame: Every 9 weeks for the first year on study ]
• Part 1 and 2: Change in the number of Tumor Infiltrating Lymphocytes(TILs) and the ratio of CD8+ lymphocytes to FOXP3+ cells infiltrating tumor post-treatment versus pretreatment by IHC [ Time Frame: Up to 5 weeks on study treatment ]

Original Secondary Outcome Measures (submitted: January 4, 2016)

• Objective Response Rate (ORR) as determined by radiographic disease assessments per immune-related Response Evaluation Criteria In Solid Tumors (irRECIST) v1.1 criteria [ Time Frame: Every 9 weeks for the first year on study ]
• Progression Free Survival (PFS) as measured by the duration from the date of first dose until the earliest date of disease progression or death as measured by immune-related Response Evaluation Criteria In Solid Tumors (irRECIST) v1.1 [ Time Frame: Every 9 weeks for the first year on study ]
• Duration of response (DOR) as measured from the time of the earliest response complete response (CR) or partial response (PR) until disease progression per irRECIST v1.1 [ Time Frame: Every 9 weeks for the first year on study ]

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
• Official Title: A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Pembrolizumab + INCB Combinations in Advanced Solid Tumors

Brief Summary

This is an open-label, multicenter, Phase 1b platform study in subjects with advanced or metastatic solid tumors (Part 1a) and subjects with selected solid tumors (Part 1b and Part 2). Two treatment groups (Group A and Group B) will be evaluated

Part 1a utilizes a 3+3 design to evaluate pembrolizumab and INCB combinations in advanced solid tumors. Group A will evaluate a JAK inhibitor with JAK1 selectivity itacitinib (INCB039110) in combination with pembrolizumab (MK-3475) and Group B will evaluate a PI3K-delta inhibitor (INCB050465) in combination with pembrolizumab to determine the maximum tolerated dose (MTD) or PAD and recommend a dose for the Part 1b safety expansion with each combination.

Once the recommended dose has been identified in Part 1a, subjects with select solid tumor types will be enrolled into safety expansion cohorts based upon prior treatment history with a PD-1 pathway-targeted agent (Part 1b) for each combination.

Part 2 utilizes a Simon 2-Stage design to evaluate INCB050465 in combination with pembrolizumab in patients with small cell lung cancer (SCLC) and a 1 stage design to evaluate the combination in patients with non-small cell lung cancer (NSCLC) and urothelial cancer (UC).

Detailed Description

This is an open-label, Phase 1b, 3 Part (Part 1a, Part 1b, and Part 2), multi-center study.

Part 1a utilizes a 3+3 design to evaluate pembrolizumab and INCB combinations in advanced solid tumors. Group A will evaluate a JAK inhibitor with JAK1 selectivity itacitinib (INCB039110) in combination with pembrolizumab (MK-3475) and Group B will evaluate a PI3K-delta inhibitor (INCB050465) in combination with pembrolizumab to determine the maximum tolerated dose (MTD) or PAD and recommend a dose for the Part 1b safety expansion with each combination.

Once the recommended dose has been identified in Part 1a, subjects with endometrial cancer, gastric cancer, melanoma, microsatellite unstable (MSI) colorectal cancer or other MMR-deficient tumors, non-small cell lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, triple negative breast cancer, pancreatic ductal carcinoma, or transitional cell carcinoma of the genitourinary tract will be enrolled into safety expansion cohorts based upon prior treatment history with a PD-1 pathway-targeted agent (Part 1b) for each combination.

Part 2 utilizes a Simon 2-Stage design to evaluate INCB050465 in combination with pembrolizumab in patients with small cell lung cancer (SCLC) and a 1 stage design to evaluate the combination in patients with non-small cell lung cancer (NSCLC) and urothelial cancer (UC).

• Study Type: Interventional
• Study Phase: Phase 1
• Study Design: Allocation: Non-Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment

Condition

• Colorectal Cancer (CRC)
• Endometrial Cancer
• Melanoma
• Head and Neck Cancer
• Lung Cancer
• MMR-deficient Tumors
• Breast Cancer
• Pancreatic Cancer
• Renal Cell Carcinoma (RCC)
• Solid Tumors
• UC (Urothelial Cancer)

Intervention

• Drug: Pembrolizumab
  Pembrolizumab 200 mg IV Q3W.
• Drug: itacitinib
  Itacitinib tablets administered orally once daily.
  Other Name: INCB039110
• Drug: INCB050465
  INCB050465 tablets administered orally once daily.

Study Arms

• Experimental: pembrolizumab + itacitinib

  Part 1a Group A will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.

  Part 1b Group A-1 and Group A-2 will evaluate the MTD or PAD of itacitinib in combination with pembrolizumab in subjects with select solid tumors.

  Interventions:

  • Drug: Pembrolizumab
  • Drug: itacitinib
• Experimental: pembrolizumab + INCB050465

  Part 1a Group B will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.

  Part 1b Group B-1 and Group B-2 will evaluate the MTD or PAD of INCB050465 in combination with pembrolizumab in subjects with select solid tumors.

  Part 2 will evaluate the combination of INCB050465 in combination with pembrolizumab in subjects with small cell lung cancer, non-small lung cancer and urothelial cancer.

  Interventions:

  • Drug: Pembrolizumab
  • Drug: INCB050465

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Active, not recruiting
• Actual Enrollment (submitted: June 7, 2019): 159
• Original Estimated Enrollment (submitted: January 4, 2016): 78
• Estimated Study Completion Date: December 24, 2021
• Actual Primary Completion Date: November 7, 2019 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Male or female, age 18 years or older.
• Willingness to provide written informed consent for the study.
• Has a core or excisional baseline tumor biopsy specimen available or willingness to undergo a pre study treatment tumor biopsy to obtain the specimen.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
• Presence of measureable disease based on RECIST v1.1
• For Part 1a: Subjects with histologically or cytologically confirmed advanced or metastatic solid tumors that have failed prior standard therapy (including subject refusal or intolerance).
• For Part 1b: Subjects with histologically or cytologically confirmed advanced or metastatic endometrial cancer, gastric cancer, melanoma, microsatellite unstable (MSI) colorectal cancer or other MMR-deficient tumors, non-small cell lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, triple negative breast cancer, pancreatic ductal carcinoma, or transitional cell carcinoma of the genitourinary tract that have had disease progression after available therapies for advanced or metastatic disease that are known to confer clinical benefit, been intolerant to treatment, or refused standard treatment.
• For Part 1b: Must have documented confirmed disease progression on a prior PD-1 pathway targeted agent or must be PD-1 pathway-targeted treatment naïve.

For Part 2

For subjects with SCLC:

Subjects with histologically or cytologically confirmed advanced or metastatic SCLC. Must not have had previous treatment with antibodies that modulate T-cell function or checkpoint pathways. Must have disease progression on or after platinum-based chemotherapy or must be intolerant to or refuse standard treatment. Must not have received more than 2 lines of prior therapy.

For subjects with NSCLC:

Subjects with a histologically or cytologically confirmed diagnosis of Stage IIIB, Stage IV, or recurrent NSCLC. Have not received more than 1 prior systemic therapy for metastatic NSCLC. No prior therapy with checkpoint inhibitors (anti-PD-1/PD-L1 or anti-CTLA-4). Have confirmation that EGFR or ALK-directed therapy is not indicated as primary therapy (documentation of absence of tumor activating EGFR mutations AND ALK gene rearrangements treatable with a tyrosine kinase inhibitor (TKI) OR presence of a KRAS mutation). If participant's tumor is known to have a predominantly squamous histology, molecular testing for EGFR mutation and ALK translocation will not be required as this is not part of current diagnostic guidelines. Have measurable disease based on RECIST 1.1.

For subjects with UC:

Subjects with a histologically or cytologically confirmed diagnosis of advanced/unresectable (inoperable) or metastatic urothelial cancer of the renal pelvis, ureter, bladder, or urethra. Have had 1 prior treatment of systemic chemotherapy containing a platinum agent or is considered ineligible to receive cisplatin-based combination therapy. No prior therapy with checkpoint inhibitors (anti-PD-1/PD-L1 or anti-CTLA-4). Have measurable disease based on RECIST 1.1.

Exclusion Criteria:

• Laboratory parameters not within the protocol-defined range.
• Receipt of anticancer medications or investigational drugs within a defined interval before the first administration of study drug.
• Received an immune-suppressive based treatment for any reason within 14 days prior to the first dose of study treatment.
• Has not recovered from toxic effect of prior therapy to < Grade 1.
• Active or inactive autoimmune process.
• Has received a live vaccine within 30 days of planned start of study therapy.
• Active infection requiring systemic therapy.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT02646748
• Other Study ID Numbers: 39110-107
• Has Data Monitoring Committee: No
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Responsible Party: Incyte Corporation
• Study Sponsor: Incyte Corporation
• Collaborators: Not Provided

Investigators

• Study Director: Mark Jones, MD; Incyte Corporation

• PRS Account: Incyte Corporation
• Verification Date: December 2020